Treatment and prescribing trends of antihypertensive drugs in 2.7 million UK primary care patients over 31 years: a population-based cohort study

Julie Rouette, Emily G. McDonald, Tibor Schuster, James M. Brophy, Laurent Azoulay

ABSTRACT

Objectives To describe the prescribing trends of antihypertensive drugs in primary care patients and assess the trajectory of antihypertensive drug prescriptions, from first-line to third-line, in patients with hypertension according to changes to the United Kingdom (UK) hypertension management guidelines.

Design Population-based cohort study.

Setting and participants We used the UK Clinical Practice Research Datalink, an electronic primary care database representative of the UK population. Between 1988 and 2018, we identified all adult patients with at least one prescription for a thiazide diuretic, angiotensin-converting enzyme (ACE) inhibitor, angiotensin receptor blocker, beta-blocker or calcium channel blocker (CCB).

Primary and secondary outcome measures We estimated the period prevalence of patients with antihypertensive drug prescriptions for each calendar year over a 31-year period. Treatment trajectory was assessed by identifying patients with hypertension newly initiating an antihypertensive drug, and treatment changes were defined by a switch or add-on of a new class. This cohort was stratified before and after 2007, the year following important changes to UK hypertension management guidelines.

Results The cohort included 2,709,241 patients. The prevalence of primary care patients with antihypertensive drug prescriptions increased from 7.8% (1988) to 21.9% (2018) and was observed for all major classes except thiazide diuretics. Patients with hypertension initiated thiazide diuretics (36.8%) and beta-blockers (23.6%) as first-line drugs before 2007, and ACE inhibitors (39.9%) and CCBs (31.8%) after 2007. After 2007, 17.3% were not prescribed guideline-recommended first-line agents. Overall, patients were prescribed a median of 2 classes (IQR 1–2) after first-line treatment.

Conclusion Nearly one-quarter of primary care patients were prescribed antihypertensive drugs by the end of the study period. Most patients with hypertension initiated guideline-recommended first-line agents. Not all patients, particularly females, were prescribed recommended agents however, potentially leading to suboptimal cardiovascular outcomes. Future research should aim to better understand the implication of this finding.

STRENGTHS AND LIMITATIONS OF THIS STUDY

- The use of the Clinical Practice Research Datalink (CPRD) allowed for the inclusion of 2.7 million primary care patients and a 31-year follow-up period.
- We conducted a detailed analysis of the antihypertensive drugs prescribed in patients with hypertension, up to the third-line, capturing changes in the pharmacological management of hypertension over time.
- The CPRD captures prescriptions issued by general practitioners and does not capture dispensing information.
- The first-ever prescription might not have been captured for some patients, although the use of a 1-year look-back period should have minimised this limitation.

INTRODUCTION

Antihypertensive drugs are commonly prescribed drugs, with a prevalence ranging between 8% and 35% of the adult population. There are five major classes, comprised of thiazide diuretics, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), beta-blockers and calcium channel blockers (CCBs). These classes have been approved for several years, with ARBs being the latest first-line class introduced in the market in 1995.

Despite a long-standing prescribing history, the prescription prevalence of antihypertensive drugs over time has not been comprehensively evaluated. Further, evidence suggests that sex differences may exist in the prescription of different antihypertensive drug classes in primary care settings. Changes to hypertension management over time have also led to earlier treatment initiation in the disease course, and in younger patients. To better understand these issues, there is a need for large country-specific studies describing the different patient-specific studies being prescribed.
these drugs and the changes in antihypertensive treatment over time.

Additionally, although guidelines have been published on the pharmacological treatment of patients with hypertension, few studies have investigated the application of these guidelines in real-world clinical practice. This gap in the literature is important because in the United Kingdom (UK) specifically, thiazide diuretics and beta-blockers were recommended first-line treatment in early guidelines, and gradually replaced by ACE inhibitors, ARBs and CCBs in later guidelines. A comprehensive assessment is thus needed to capture the treatment trajectory of patients with hypertension over time and identify potential gaps and inequities in best practice management of hypertension.

Therefore, the aims of this population-based study were to describe the long-term prescribing trends of antihypertensive drugs in UK primary care patients and define the trajectory of antihypertensive drug prescriptions, from first-line to third-line, in primary care patients with hypertension.

**METHODS**

**Data source**

This study was conducted using the UK Clinical Practice Research Datalink (CPRD) Gp OnLine Data (GOLD), a large primary care database of electronic medical records representative of the UK population. The CPRD contains demographic information, anthropometric data such as body mass index (BMI), and lifestyle variables such as smoking. Medical diagnoses, laboratory test results, procedures and specialist referrals are recorded using Read codes, and prescriptions details are recorded using the British National Formulary (BNF) dictionary. Patient records provided by the general practices are assessed for quality through the Quality and Outcomes Framework, with lifestyle variables such as smoking, blood pressure, BMI, and alcohol intake having over 70% completeness in the CPRD. The CPRD has also been shown to be representative of the UK population for age, sex, ethnicity and BMI distribution, and diagnoses have been shown to have high sensitivity and specificity.

**Study population**

Using the CPRD, we first identified a cohort of patients at least 18 years of age and registered with a general practice between 1 January 1988 and 31 December 2018. Cohort entry was defined as the patient’s start of registration with the general practice, the date the general practice met data quality standards, or 1 January 1988, whichever came later. End of follow-up was defined as the patient’s end of registration with the general practice, death from any cause, or 31 December 2018, whichever came first. Within this cohort, we identified patients who received at least one antihypertensive drug prescription during the study period, with no restrictions on specific comorbidities as these drugs can be prescribed for different indications. These drugs consisted of all those available in the UK during the study period and included thiazide and thiazide-like diuretics, ACE inhibitors, ARBs, beta-blockers, CCBs, other diuretics (loop diuretics, potassium-sparing diuretics, other diuretics), and other agents (alpha-blockers, alpha agonists, direct-acting vasodilators, centrally acting agents, ganglion-blocking agents, direct renin inhibitors and combination pills) (BNF codes in online supplemental table 1).

**Statistical analyses**

**Period prevalence of patients with antihypertensive drug prescriptions**

We first estimated the period prevalence of primary care patients prescribed antihypertensive drugs, overall and stratified by antihypertensive drug class, in each calendar year of the study period. Period prevalence was calculated by dividing the number of patients who were prescribed an antihypertensive drug by the total number of patients in the CPRD in each calendar year during the study period. Second, we assessed the period prevalence among patient subgroups, including by sex and age (18–39, 40–59, 60–79, ≥80 years), and by indications of use (hypertension, heart failure, coronary heart disease, diabetes and chronic kidney disease). The latter was calculated by dividing the number of patients with a given indication and a prescription for a specific antihypertensive drug class by the total number of patients prescribed any antihypertensive drug with that indication. This analysis was conducted to describe the patient population with these specific conditions. Finally, we estimated the number of antihypertensive drug classes prescribed to primary care patients over the study period overall, by sex, and by age group, to better understand changes in treatment intensity over time in primary care.

**Characteristics of patients initiating a first-ever antihypertensive drug**

To better understand the patient population initiating antihypertensive drugs, we identified all patients aged 18 and above with a first prescription for an antihypertensive drug between 1 January 1988 and 31 December 2018. Cohort entry corresponded to the date of the first-ever antihypertensive drug prescription in monotherapy in the patient’s medical record. For this analysis, all patients were required to have at least 1 year of medical history in the CPRD before cohort entry. This was necessary to ascertain first-ever status and to have a sufficient look-back period to capture clinically relevant characteristics. Patient characteristics were described overall (1988–2018) and by decades (1988–1999, 2000–2009, 2010–2018). The following characteristics were captured at cohort entry: age, sex, BMI, smoking status, systolic and diastolic blood pressure (last measurement before cohort entry); and measured ever before: diagnoses of hypertension, heart failure, coronary heart disease, peripheral vascular disease, stroke, arrhythmias, atrial fibrillation, stable...
angina, myocardial infarction, diabetes, and chronic kidney disease.

Finally, as recent evidence has shown an increase in beta-blocker prescriptions for non-cardiovascular conditions over time,20 we described the distribution of this drug class in patients with a first-ever and ever prescription.

Treatment trajectory
We also assessed the treatment trajectory among patients initiating a first-line antihypertensive drug in monotherapy before and after 1 January 2007. This dichotomisation was based on the June 2006 pharmacological update of the 2004 National Institute for Health and Care Excellence (NICE) guidelines on hypertension in primary care.13 14 These guidelines newly recommended ACE inhibitors (or ARBs if ACE inhibitors are not well tolerated) as the preferred first-line treatment in younger patients rather than beta-blockers.

For this analysis, we identified patients initiating a first-line antihypertensive drug with evidence of hypertension before cohort entry. Evidence of hypertension was defined by either a diagnosis of hypertension before cohort entry or by at least three elevated systolic (≥140 mm Hg) or diastolic (≥90 mm Hg) blood pressure measurements in the year before cohort entry.21 Patients were followed from their initial first-line treatment to subsequent treatment lines up to the third-line. A change in treatment line was defined by a patient switching a drug class to a new drug class or adding on a new drug class. End of follow-up was defined as the last prescription date on record. At each treatment line, we captured the new drug class and calculated the median number of days between each treatment change (from the date of the first prescription of the first-line drug to the date of the first prescription of the second-line drug, and so on).

Finally, to describe treatment intensity, we calculated the number of antihypertensive drug classes prescribed after failure on first-line monotherapy treatment over the study period. All analyses were performed with SAS V.9.4 (SAS Institute).

Patient and public involvement
Patients and the public were not involved in the design and implementation of the study (as this study involved the use of secondary data), or in dissemination plans.

RESULTS
Period prevalence of patients with antihypertensive drug prescriptions
Within a cohort of 11 417 758 primary care patients, 2 709 241 patients were prescribed at least one antihypertensive drug during the study period. Overall, the prevalence of patients with antihypertensive drug prescriptions increased from 7.8% in 1988 to 21.9% in 2018, and has remained relatively steady since 2006 (figure 1). By the end of the study period, 51.0% of patients were prescribed two or more antihypertensive drug classes.

Figure 2 presents the period prevalence for each antihypertensive drug class during the study period. Between 1988 and 2018, the prevalence increased for ACE inhibitors (0.4% vs 9.3%), CCBs (1.4% vs 8.7%) and beta-blockers (2.6% vs 8.6%). The prevalence of patients prescribed ARBs modestly increased from 0% in 1995 (the year ARBs entered the UK market) to 4.0% in 2018. For thiazide diuretics, the prevalence decreased from a peak of 7.3% in 2005 to 3.8% in 2018. In 2018, ACE inhibitors represented 24.5% of all antihypertensive drug prescriptions, followed by CCBs (22.9%), beta-blockers (22.5%), ARBs (10.4%), thiazide diuretics (9.9%), other diuretics

![Figure 1](https://example.com/figure1.png)
(8.3%) and other antihypertensive drugs (1.4%). Treatment intensity increased during the study period (online supplemental figure 1), with patients being prescribed a median of 1 drug class (IQR 1–2, maximum 7) in 1988 to 2 (IQR 1–2, maximum 7) in 2018. During the study period, female patients were more likely than male patients to be prescribed only one class (52.5% vs 45.3% in 2018, respectively) (online supplemental figure 2A,B). Patients aged 60 and over were increasingly more likely to be prescribed two or more classes (online supplemental figure 3A–D).

Online supplemental figure 4A–G presents the period prevalence for males and females by age groups. Female patients were consistently more likely to be prescribed thiazide diuretics compared with male patients throughout the study period. In contrast, male patients were more likely to be prescribed ACE inhibitors than females, across all age groups. Similarly, males were more commonly prescribed CCBs during the study period, except for the youngest (18–39 years old) and oldest (80+) age groups. Finally, the prevalence of patients aged 18–39 years with beta-blocker prescriptions increased from 0.3% in 1988 to 1.9% for males and to 4.0% for females in 2018.

Online supplemental figures 5–9 show the prevalence of antihypertensive drugs for patients with hypertension, heart failure, coronary heart disease, diabetes and chronic kidney disease, respectively, to describe the patient population with these conditions. In patients with hypertension, the prevalence of patients with beta-blocker and thiazide diuretic prescriptions was highest from 1988 until 2005–2006, when the 2004 guideline and the 2006 pharmacological update began primarily recommending ACE inhibitors and CCBs for the management of hypertension (online supplemental figure 5). In patients with heart failure, the most prevalent drug classes were diuretics (since 1988), ACE inhibitors (since 1992) and beta-blockers (since 2003) (online supplemental figure 6). Beta-blockers were contraindicated for chronic heart failure until the publication of guidelines in 1997 after which the prevalence rose rapidly, becoming the most prevalent class by the end of the study period. Patients with coronary heart disease and type 2 diabetes showed a similar pattern, with the highest prevalence for ACE inhibitors, beta-blockers and CCBs, particularly after 2000 (online supplemental figures 7,8). Finally, among patients with chronic kidney disease, the prevalence of patients with ACE inhibitors, CCBs, beta-blockers and loop diuretics was highest for most of the study period, however with a sharp decline for loop diuretics in 2006 coinciding with the publication of the Quality and Outcomes Framework for chronic kidney disease in England and the UK chronic kidney disease management guidelines (online supplemental figure 9).

### Characteristics of patients initiating a first-ever antihypertensive drug

There were 1 425 542 patients initiating a first-ever antihypertensive drug prescription in monotherapy during the study period (online supplemental figure 10); 44.6% of those were males, and the mean age was 55.4 years (SD: 17.2).

Table 1 describes the characteristics of patients initiating first-ever antihypertensive drugs, overall and by drug class, during the study period. Beta-blockers represented...
| Table 1 Baseline characteristics of primary care patients with a first-ever antihypertensive drug prescription between 1 January 1988 and 31 December 2018 |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| | Thiazide diuretics | ACE inhibitors | ARBs | Beta-blockers | CCBs | Other diuretics | Other* | Total |
|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|-----------------|
| Total | 202 856 (14.9) | 237 923 (17.5) | 17 846 (1.3) | 494 333 (36.4) | 196 485 (14.5) | 157 994 (11.6) | 52 632 (3.9) | 1 360 069 |
| Males, n (%) | 75 317 (37.1) | 149 293 (62.7) | 10 731 (60.0) | 201 755 (40.1) | 103 536 (52.7) | 60 632 (38.4) | 53 53 (10.2) | 606 617 (44.6) |
| Mean age, years (SD) | 63.2 (14.5) | 55.3 (13.0) | 57.0 (13.4) | 45.9 (16.7) | 61.5 (14.1) | 65.9 (17.7) | 53.5 (12.0) | 55.4 (17.2) |
| Mean BMI, kg/m² (SD) | 27.7 (5.4) | 29.4 (6.0) | 28.8 (5.8) | 26.2 (5.4) | 27.5 (5.4) | 27.6 (6.8) | 26.8 (5.3) | 27.4 (5.8) |
| Smoking status | Current | 54 949 (27.1) | 58 332 (24.5) | 4212 (23.6) | 155 440 (31.4) | 46 474 (23.6) | 43 226 (27.4) | 15 851 (30.1) | 378 484 (27.8) |
| | Never | 94 945 (46.8) | 114 852 (48.3) | 8808 (49.4) | 227 370 (46.0) | 94 175 (47.9) | 64 733 (41.0) | 23 988 (45.5) | 628 851 (45.2) |
| | Past | 32 981 (16.3) | 57 318 (24.0) | 3830 (21.5) | 74 052 (15.0) | 46 490 (23.6) | 28 990 (18.3) | 7668 (14.6) | 251 329 (18.5) |
| | Unknown | 19 981 (9.8) | 7421 (3.1) | 996 (5.6) | 37 471 (7.6) | 9346 (4.8) | 21 045 (13.3) | 5145 (9.8) | 101 405 (7.5) |
| Mean blood pressure, mm Hg (SD) | | | | | | | | |
| | Systolic | | | | | | | |
| | Diastolic | | | | | | | |
| Hypertension†† | 144 530 (71.2) | 181 752 (76.4) | 13 668 (76.6) | 113 052 (22.9) | 133 362 (67.9) | 22 232 (14.1) | 11 388 (21.6) | 619 984 (45.6) |
| Year of initiation, n (%) | | | | | | | | |
| | 1988–1993 | 10 748 (5.3) | 2683 (1.1) | 0 | 20 137 (4.1) | 6182 (3.1) | 11 944 (7.6) | 5463 (10.4) | 57 157 (4.2) |
| | 1994–1999 | 37 126 (18.3) | 11 124 (4.7) | 588 (3.3) | 60 356 (12.2) | 16 230 (8.3) | 28 427 (18.0) | 7424 (14.1) | 161 275 (11.9) |
| | 2000–2005 | 105 496 (52.0) | 51 364 (21.6) | 7514 (42.1) | 142 009 (28.7) | 32 484 (16.5) | 46 137 (29.2) | 15 888 (30.2) | 400 892 (29.5) |
| | 2006–2011 | 41 214 (20.3) | 107 238 (45.1) | 6174 (34.6) | 131 472 (26.6) | 68 823 (35.0) | 41 638 (26.4) | 14 726 (28.0) | 411 285 (30.2) |
| | 2012–2018 | 8272 (4.1) | 65 514 (27.5) | 3570 (20.0) | 140 359 (28.4) | 72 766 (37.0) | 29 848 (18.9) | 9131 (17.3) | 329 460 (24.2) |
| Medical history, n (%)‡‡ | | | | | | | | |
| Heart failure | 1107 (0.5) | 3024 (1.3) | 100 (0.6) | 1234 (0.7) | 403 (0.2) | 9852 (6.2) | 269 (0.5) | 15 989 (1.2) |
| Coronary heart disease § | 19 310 (9.5) | 25 597 (10.8) | 1457 (8.2) | 48 243 (9.4) | 24 899 (12.7) | 17 680 (11.2) | 2344 (4.5) | 137 530 (10.1) |
| Peripheral vascular disease | 4233 (2.1) | 5751 (2.4) | 316 (1.8) | 3877 (0.8) | 6813 (3.5) | 5781 (3.7) | 482 (0.9) | 27 353 (2.0) |
| Stroke | 5090 (2.5) | 8577 (3.6) | 392 (2.2) | 4395 (0.9) | 5079 (2.6) | 5766 (3.6) | 449 (0.9) | 29 752 (2.2) |
| Arrhythmias | 3768 (1.9) | 5343 (2.2) | 379 (2.1) | 27 442 (5.6) | 6756 (3.4) | 9326 (5.9) | 512 (1.0) | 53 526 (3.9) |
| Atrial fibrillation | 2676 (1.3) | 3916 (1.6) | 271 (1.5) | 19 669 (4.0) | 4214 (2.1) | 7977 (5.0) | 292 (0.6) | 39 015 (2.9) |
| Stable angina | 3246 (1.6) | 5233 (2.2) | 279 (1.6) | 19 313 (3.9) | 8912 (4.5) | 4267 (2.9) | 412 (0.8) | 42 022 (3.1) |
| Myocardial infarction | 1446 (0.7) | 6873 (2.9) | 262 (1.5) | 11 846 (2.4) | 2930 (1.5) | 3755 (2.4) | 175 (0.3) | 27 287 (2.0) |
| Diabetes | 21 707 (10.7) | 80 306 (33.8) | 4503 (25.2) | 59 012 (11.9) | 32 154 (16.4) | 20 901 (13.2) | 7221 (13.7) | 225 813 (16.6) |
| Chronic kidney disease | 1991 (1.0) | 11 522 (4.8) | 686 (3.8) | 4707 (1.0) | 6018 (3.1) | 4248 (2.8) | 444 (0.8) | 29 796 (2.2) |

*Other antihypertensive drugs.
†Defined as a recorded diagnosis of hypertension or at least three elevated systolic (≥140) or diastolic (≥90) blood pressure readings in the year before cohort entry.
‡Non-mutually exclusive categories.
§Includes stable ischaemic heart disease (chronic coronary syndrome), carotid artery disease (carotid stenosis) and peripheral artery disease.
ACE, angiotensin-converting enzyme; ARBs, angiotensin II receptor blockers; BMI, body mass index; CCBs, calcium channel blockers.
the most commonly initiated drugs (36.4%), followed
by ACE inhibitors (17.5%). Males were more likely
to receive ACE inhibitors, ARBs and CCBs (62.7%, 60.0% and
52.7%, respectively), while females were more likely
to receive thiazide diuretics, beta-blockers, other diuretics
and other antihypertensive drugs (62.9%, 59.9%, 61.6%,
89.8%, respectively). The majority of prescriptions in the
‘Other antihypertensive drugs’ category (71.3%) were for
clonidine hydrochloride 0.025 mg tablets.

Most patients initiating a thiazide diuretic, ACE inhibitor,
ARB and CCB had evidence of hypertension (71.2%,
76.4%, 76.6% and 67.9%, respectively). In contrast,
patients initiating a beta-blocker, other diuretics and other
antihypertensive drugs were less likely to have evidence
of hypertension (22.9%, 14.1% and 21.6%, respectively).
The majority of first-ever beta-blocker prescriptions were
for propranolol (online supplemental table 2).

Online supplemental tables 3–5 describe the charac-
teristics of patients initiating a first-ever antihypertensive
Between the first and the third decades, there was an
overall increase in the proportion of patients diagnosed
with diabetes (8.9% vs 21.3%) and chronic kidney disease
(0.3% vs 3.6%), as well as hypertension for ACE inhibi-
tors (71.4% vs 78.2%), CCBs (44.2% vs 73.8%) and other
diuretics (10.6% vs 16.8%).

**Treatment trajectory**
The trajectory analysis included a total of 619,984 patients
with hypertension, comprised of 317,210 patients initi-
ating a first-line antihypertensive drug in the pre-2007
cohort and 302,774 patients in the post-2007 cohort.
Online supplemental tables 6,7 present the baseline
characteristics of these patients. Patients in the pre-2007
cohort were slightly older than the post-2007 cohort
(60.5 years, SD: 18.3) vs 58.1 years, SD: 14.0) and had a
higher pretreatment mean systolic (166.2 mm Hg, SD:
17.9 vs 161.1 mm Hg, SD: 16.5) and diastolic blood pres-
sure (94.9 mm Hg, SD: 10.6 vs 93.4 mm Hg, SD: 10.7).
In contrast to 53.2% of patients in the post-
2007 cohort, 79.4% of patients
switched to or added-on a new antihypertensive drug in
contrast to 53.2% of patients in the post-2007 cohort
(online supplemental table 8).

**Figure 3** presents the treatment trajectory of patients
initiating an antihypertensive drug before 1 January
2007. In this cohort, thiazide diuretics (36.8%) and
beta-blockers (23.6%) were the most common first-line
drugs. Among patients with first-line thiazide diuretic
prescriptions, ACE inhibitors and beta-blockers were the
most common second-line treatment (26.9% and 25.6%,
respectively). Among patients with first-line beta-blocker
prescriptions, thiazide diuretics and ACE inhibitors were
the most common second-line treatment (23.7% and
22.6%, respectively). Treatment trajectory details for
ARBs and ‘Others’ are in online supplemental figure 11.

**DISCUSSION**
**Principal findings**
In this large population-based study, the prevalence of
patients prescribed antihypertensive drugs increased
during the study period but has remained relatively
stable since 2006, with 21.9% of primary care patients
receiving antihypertensive drugs by the end of the study
period. The prescription prevalence was highest for ACE
inhibitors (24.5%), CCBs (22.9%) and beta-blockers (22.5%).
Beta-blockers were most prevalent in females
and in youngest and oldest patients. Most patients with
hypertension initiated guideline-recommended first-line
agents, with thiazide diuretics and beta-blockers repre-
senting the most common first-line drugs before 2007
(36.8% and 23.6%, respectively) and ACE inhibitors and
CCBs after 2007 (39.9% and 31.8%, respectively). Fewer
females initiated recommended first-line agents.

**Comparison with previous studies**
Although previous studies have described prescribing
trends of antihypertensive drugs in UK primary care
practices, these trends were reported for specific patient
categories, indications, drug classes, or over short time
periods.7–25,37 As such, there was a gap in the literature for
a comprehensive assessment of the prescribing practices
in primary care settings over time. In our study, 8% of
adult primary care patients were prescribed antihyperten-
sive drugs in 1988 and increasing to 22% by the end of the
study period. Similarly, other countries and jurisdictions
have reported an overall prevalence ranging between
8% and 35% in adult populations, with an increase over...
time. A large pooled analysis of 104 million primary care individuals found that the age-standardised prevalence of hypertension doubled between 1990 and 2019 in primary care patients aged 30–79. Countries such as Canada, Peru and the UK (in women only) reported the lowest prevalence of hypertension, representing less than 25% of its primary care population. Hypertension treatment was highest in Canada, South Korea and Iceland, representing over 70% of patients with hypertension, but reported to be only 47% in the UK.

The prevalence of patients with ACE inhibitor and CCB prescriptions has increased steadily over the last three decades, while it has decreased sharply for thiazide diuretics since 2005. Similarly, a previous UK study reported a decrease in the number of thiazide diuretic prescriptions between 2010 and 2016/2017. Changes in UK hypertension treatment guidelines, notably in 2004 when ACE inhibitors and CCBs were newly recommended as first-line treatment for hypertension along with thiazide diuretics and beta-blockers, may have contributed to this decline. Indeed, this decreasing trend was also seen in our findings specific to patients with hypertension. As thiazide diuretics have been associated with lower treatment adherence compared with ACE inhibitors, ARBs and CCBs, this could have led clinicians to favour other classes with higher adherence. Indeed, we observed a shorter number of days between treatment changes in patients with thiazide diuretic prescriptions relative to other drugs. Concerningly, as we consistently observed more female patients being prescribed thiazide diuretics throughout the study period, lower treatment adherence could lead to suboptimal blood pressure control in women.

Figure 3  Treatment trajectory of primary care patients with hypertension with a first-ever antihypertensive drug prescription before 1 January 2007. Each concentric circle represents a treatment line. Percentages do not reach 100% as only patients who switched to or added-on a new drug class are included. Fewer patients were prescribed first-line ARBs and ‘Other’ antihypertensive drugs, resulting in thinner slices for these two classes. As such, details of third-line results for ARB and ‘Other’ are in online supplemental figure 11 to better visualise the results. ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker.
A large 2020 systematic review and meta-analysis of sex differences in cardiovascular medication prescriptions in primary care patients found that women were 27% more likely to be prescribed thiazide diuretics but less likely to be prescribed ACE inhibitors (pooled prevalence ratio 0.83%, 95% CI 0.78 to 0.89). Over the study period, our study consistently showed a higher prevalence of female patients with thiazide diuretic prescriptions and a lower prevalence with ACE inhibitor prescriptions compared with male patients, similar to previous large studies of primary care patients. This sex difference may perhaps be explained by dissimilar presentations of cardiovascular symptoms, or different reporting of adverse events in men compared with women. Indeed, a 2019 systematic review of adverse reactions to heart failure drugs showed that cough and angioedema were reported more frequently in women treated with ACE inhibitors than men. These factors may in turn be reflected in the clinical decisions leading to prescribing practices. Nonetheless, further research should focus on better understanding these sex differences in prescribing practices.

Figure 4 Treatment trajectory of primary care patients with hypertension with a first-ever antihypertensive drug prescription after 1 January 2007. Each concentric circle represents a treatment line. Percentages do not reach 100% as only patients who switched to or added-on a new drug class are included. Fewer patients were prescribed first-line ARBs and ‘Other’ antihypertensive drugs, resulting in thinner slices for these two classes. As such, details of third-line results for ARB and ‘Other’ are in online supplemental figure 13 to better visualise the results. ACE, angiotensin-converting enzyme; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker.
of patients aged 18–39 with a beta-blocker prescription increased over time, most markedly since 2007. Similarly, between 1999–2000 and 2011–2012, a US study found a nearly eightfold increase in the prevalence of adults aged 20–39 with non-cardioselective beta-blocker prescriptions. Our study also showed that the majority of those first-ever prescriptions were for propranolol. Indeed, a recent study reported a 2.5-fold increase in the prevalence of propranolol prescriptions for anxiety in UK primary care practices between 2003 and 2018, with a higher incidence for female patients and patients aged <45 years old. This increase in prescriptions may correspond to the increase in the recording of anxiety symptoms and diagnoses in female and younger patients in recent years. Although propranolol is licensed for use in anxiety symptoms management, there is currently limited evidence of their long-term effectiveness and safety, and no specific recommendations exist from NICE regarding its use in anxiety. Further, the UK Healthcare Safety Investigation Branch recently informed of a potential risk of propranolol toxicity in overdose, reporting a 33% increase in deaths potentially associated with propranolol overdose between 2012 and 2017. Our study also found a sharp increase in patients aged 80 and over with beta-blocker prescriptions, representing the largest age group with prescriptions for this class. Beta-blockers, and specifically non-cardioselective beta-blockers such as propranolol, have been associated with increased risk of fall in the elderly. Together, these findings warrant further investigation to understand the benefits and safety of beta-blockers, especially propranolol.

National guidelines recommend select first-line agents for antihypertensive treatment. Published by the British Hypertension Society in 1989, the first guideline recommended thiazide diuretics and beta-blockers as first-line treatments. At that time, ACE inhibitors and CCBs were new agents with limited evidence of their efficacy. Similar recommendations were made in subsequent guidelines, although ACE inhibitors, CCBs, alpha-blockers and later, ARBs could be considered potential options. As more evidence became available from randomised controlled trials and hypertension treatment became more complex, NICE and the British Hypertension Society published four new guidelines and updates (2004, 2006, 2011, 2019) recommending ACE inhibitors and CCBs as first-line agents and introducing treatment choice based on age and ethnicity. Our findings showed that patients treated after 2007 were younger and had lower mean blood pressure measurements than those treated before 2007. This is consistent with recent improvements in hypertension management which have led to the earlier treatment of patients, those younger in age, and those with lower initial blood pressure. However, much remains to be done. Previous studies showed that patients initiating an ACE inhibitor or a CCB had similar reductions in blood pressure, regardless of age, suggesting that treatment choice based on indications rather than age might be more important.

The treatment trajectories reported in our study reflected the UK hypertension management guidelines published during the study period, with thiazide diuretics and beta-blockers being the most common first-line agents in the pre-2007 cohort and ACE inhibitors and CCBs in the post-2007 cohort. Similarly, one UK study found that diuretics and beta-blockers were prescribed in 54% of patients between 1993–1997. More recently, another UK study found that 69.7% of patients initiated an ACE inhibitor or CCB between 2006 and 2014. In our study however, 17.3% of patients were not prescribed a guideline-recommended first-line agent after 2007 and female patients were less likely to be prescribed an ACE inhibitor, ARB or CCB, which are currently guideline-recommended first-line agents. Further, 19.5% of patients were prescribed three or more antihypertensive drug classes after failure on first-line monotherapy, with some patients being prescribed up to seven classes. These findings suggest that some patients may be less likely to receive first-line agents and more likely to be overprescribed antihypertensive drugs, potentially leading to less effective blood pressure control and higher risk of adverse effects. These gaps and inequities in best practice management of hypertension should be further investigated. Further, studies should investigate which specific treatment trajectory optimises cardiovascular outcomes in patients with hypertension.

Strengths and limitations of the study
Our study has several strengths. First, with the inclusion of 2.7 million patients, it is the largest and most comprehensive study to date on the prescribing trends of antihypertensive drugs, presenting trends by drug class, sex, age group and comorbidities. Second, the 31-year study period provides the most extended follow-up to date and captures major changes in UK treatment guidelines over time. Third, this study describes the treatment trajectory of antihypertensive drugs from first- through third-line, providing a detailed picture of the treatment lines used in the management of patients with hypertension along with the duration of each of these treatment lines. Finally, the CPRD has been shown to be representative of the UK population and undergoes regular data quality checks to ensure its validity.

Our study also has limitations. First, as the CPRD represents prescriptions issued by general practitioners, prescriptions from specialists are not captured in the database. However, in the UK, most patients treated with antihypertensive drugs are managed by general practitioners. Second, the CPRD captures prescriptions rather than dispensing information. Therefore, it is possible that some patients may not fill a prescription or adhere to the prescription. However, our study focused on the prescription rather than use of antihypertensive drugs. Third, for the treatment trajectory cohort, the analysis was limited to patients with a recorded diagnosis of hypertension through a robust algorithm. However, it is possible that some patients were not captured by this
definition, leading to an underestimation of the number of patients included in the cohort. However, there is no evidence suggesting that these patients would differ by antihypertensive drug class. Fourth, some antihypertensive drugs may have been prescribed for indications other than hypertension. However, we captured the first-ever antihypertensive drug prescription after a diagnosis of hypertension, therefore minimising the likelihood that the prescriptions were indicated for other comorbidities. Finally, it is possible that we might not have captured the first-ever prescription for some patients.

In summary, nearly one-quarter of primary care patients were prescribed antihypertensive drugs by the end of the study period, with half of those concomitantly receiving two or more classes. Beta-blockers were most prevalent in females and in both the youngest and oldest patients, although this class is associated with potential adverse events. Most patients with hypertension initiated a thiazide diuretic or beta-blocker before 2007 and an ACE inhibitor or CCB after 2007. These prescribing patterns mirror the changes in hypertension management guidelines during the study period. However, fewer females initiated recommended first-line agents, potentially leading to suboptimal cardiovascular outcomes. Future studies should investigate these gaps and inequities, as well as which specific treatment trajectory optimises cardiovascular outcomes in patients with hypertension.

Author affiliations
1Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Montreal, Quebec, Canada
2Centre for Clinical Epidemiology, Lady Davis Institute for Medical Research, Montreal, Quebec, Canada
3Division of General Internal Medicine, McGill University Health Centre, Montreal, Quebec, Canada
4Department of Experimental Medicine, McGill University, Montreal, Quebec, Canada
5Department of Family Medicine, McGill University, Montreal, Quebec, Canada
6Division of Clinical Epidemiology, McGill University Health Centre, Montreal, Quebec, Canada
7Department of Medicine, McGill University, Montreal, Quebec, Canada
8Gerald Bronfman Department of Oncology, McGill University, Montreal, Quebec, Canada

Acknowledgements JR is the recipient of a Doctoral Award from the Canadian Institutes of Health Research (FRN-152254) and a Doctoral Award from the Fonds de Recherche du Québec- Santé. EM holds a Chercheur-Clinicien Junior 1 award from the Fonds de Recherche du Québec- Santé. LA holds a Chercheur-Boursier Senior Award from the Fonds de Recherche du Québec - Santé and is the recipient of a William Dawson Scholar award from McGill University. The authors would like to thank Dr Matthew D Parsons for his valuable contributions to the final version of the manuscript.

Contributors All authors (JR, EM, TS, JB and LA) conceived and designed the study, interpreted the data, critically revised the manuscript for important intellectual content, read and approved the final version of the manuscript, and are responsible for its content. LA acquired the data. JR conducted the analyses. JR drafted the manuscript. LA attests that the manuscript is an honest, accurate and transparent account of the study being reported and that no important aspects of the study have been omitted. LA acts as the guarantor.

Funding This work was supported by a Foundation Scheme grant from the Canadian Institutes of Health Research (FDN-143328). The funding sources had no influence on the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Competing interests JR received consulting fees for work unrelated to this study from Biogen. LA received consulting fees from Janssen and Pfizer for work unrelated to this study. JB, TS and EM have no conflicts to disclose.

Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

Patient consent for publication Not applicable.

Ethics approval The study protocol was approved by the Independent Scientific Advisory Committee of the CPRD (protocol number 19_153A) and the Research Ethics Board of the Jewish General Hospital, Montreal, Canada.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement No data are available. This study is based in part on data from the Clinical Practice Research Datalink obtained under license from the UK Medicines and Healthcare products Regulatory Agency. The data are provided by patients and collected by the UK National Health Service as part of their care and support. The interpretation and conclusions contained in this study are those of the author(s) alone. Because electronic health records are classified as “sensitive data” by the UK Data Protection Act, information governance restrictions (to protect patient confidentiality) prevent data sharing via public deposition. Data are available with approval through the individual constituent entities controlling access to the data. Specifically, the primary care data can be requested via application to the Clinical Practice Research Datalink (https://www.cprd.com).

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Julie Rouette http://orcid.org/0000-0003-3882-0998
James M. Brophy http://orcid.org/0000-0001-8049-6875
Laurent Azoulay http://orcid.org/0000-0001-5162-3556

REFERENCES


Zanchetti A, Crepaldi G, Bond MG, et al. Different effects of antihypertensive treatment based on angiotensin-converting enzyme inhibitors or hydrochlorothiazide with or without lipid lowering by pravastatin on progression of asymptomatic carotid atherosclerosis: principal


SUPPLEMENTARY MATERIAL

Treatment and prescribing trends of antihypertensive drugs in 2.7 million UK primary care patients over 31 years: a population-based cohort study
Supplementary Table 1: British National Formulary codes for antihypertensive drugs
Supplementary Table 2: Distribution of beta-blockers prescriptions among patients with a first-ever and ever prescription
Supplementary Table 3: Baseline characteristics of primary care patients with a first-ever antihypertensive drug prescription between January 1, 1988 and December 31, 1999
Supplementary Table 4: Baseline characteristics of primary care patients with a first-ever antihypertensive drug prescription between January 1, 2000 and December 31, 2009
Supplementary Table 5: Baseline characteristics of primary care patients with a first-ever antihypertensive drug prescription between January 1, 2010 and December 31, 2018
Supplementary Table 6: Baseline characteristics of hypertensive primary care patients with a first-line antihypertensive drug prescription before January 1, 2007
Supplementary Table 7: Baseline characteristics of hypertensive primary care patients with a first-line antihypertensive drug prescription after January 1, 2007
Supplementary Table 8: Percentage of patients with switches and add-ons and median number of days of prescription before treatment change
Supplementary Figure 1: Percentage of primary care patients with antihypertensive drug prescriptions, stratified by treatment intensity
Supplementary Figure 2: Percentage of male (A) and female (B) primary care patients with antihypertensive drug prescriptions, stratified by treatment intensity
Supplementary Figure 3: Percentage of primary care patients with antihypertensive drug prescriptions for each age group (A-D), stratified by treatment intensity
Supplementary Figure 4: Period prevalence of primary care patients for each antihypertensive drug class (A-G), stratified by sex and age
Supplementary Figure 5: Period prevalence of primary care patients with hypertension and with antihypertensive drug prescriptions, stratified by antihypertensive drug class
Supplementary Figure 6: Period prevalence of primary care patients with heart failure and with antihypertensive drug prescriptions, stratified by antihypertensive drug class
Supplementary Figure 7: Period prevalence of primary care patients with coronary heart disease and with antihypertensive drug prescriptions, stratified by antihypertensive drug class
Supplementary Figure 8  Period prevalence of primary care patients with diabetes and with antihypertensive drug prescriptions, stratified by antihypertensive drug class

Supplementary Figure 9  Period prevalence of primary care patients with chronic kidney disease and with antihypertensive drug prescriptions, stratified by antihypertensive drug class

Supplementary Figure 10  Study flow chart of patients with a first-ever antihypertensive drug prescription in monotherapy

Supplementary Figure 11  Treatment trajectory of primary care patients with hypertension with a first-ever ARB or Other antihypertensive drug before January 1, 2007

Supplementary Figure 12  Median number of days (interquartile range) of each treatment line for primary care patients with hypertension with a first-ever antihypertensive drug prescription before January 1, 2007

Supplementary Figure 13  Treatment trajectory of primary care patients with hypertension with a first-ever ARB or Other antihypertensive drug after January 1, 2007

Supplementary Figure 14  Median number of days (interquartile range) of each treatment line for primary care patients with hypertension with a first-ever antihypertensive drug prescription after January 1, 2007

Supplementary Figure 15  Percentage of primary care patients with hypertension and antihypertensive drug prescriptions, stratified by number of antihypertensive drug classes prescribed after failure on first-line monotherapy
**Supplementary Table 1.** British National Formulary codes for antihypertensive drugs

<table>
<thead>
<tr>
<th>BNF code</th>
<th>BNF header</th>
</tr>
</thead>
<tbody>
<tr>
<td>2020100</td>
<td>Thiazides And Related Diuretics</td>
</tr>
<tr>
<td>2020200</td>
<td>Loop Diuretics</td>
</tr>
<tr>
<td>2020300</td>
<td>Potassium-sparing Diuretics And Aldosterone Antagonists</td>
</tr>
<tr>
<td>2020400</td>
<td>Potassium-sparing Diuretics With Other Diuretics</td>
</tr>
<tr>
<td>2020500</td>
<td>Osmotic Diuretics</td>
</tr>
<tr>
<td>2020600</td>
<td>Mercurial Diuretics</td>
</tr>
<tr>
<td>2020800</td>
<td>Diuretics With Potassium</td>
</tr>
<tr>
<td>2040000</td>
<td>Beta-adrenoceptor Blocking Drugs</td>
</tr>
<tr>
<td>02020100/02040000</td>
<td>Thiazides And Related Diuretics/Beta-adrenoceptor Blocking Drugs</td>
</tr>
<tr>
<td>02020100/02050501</td>
<td>Thiazides And Related Diuretics/Angiotensin-Converting Enzyme Inh</td>
</tr>
<tr>
<td>02020100/09050102</td>
<td>Thiazides And Related Diuretics/Hypercalcaemia And Hypercalciuria</td>
</tr>
<tr>
<td>02020700/11065300</td>
<td>Carbonic Anhydrase Inhibitors/Carbonic Anhydrase Inhibitors And S</td>
</tr>
<tr>
<td>02030200/02040000</td>
<td>Drugs For Arrhythmias/Beta-Adrenoceptor Blocking Drugs</td>
</tr>
<tr>
<td>02050202/02040000</td>
<td>Supraventricular Arrhythmias/Beta-Adrenoceptor Bloc</td>
</tr>
<tr>
<td>02050202/02060200</td>
<td>Supraventricular Arrhythmias/Calcium-Channel Blockers</td>
</tr>
<tr>
<td>02040000/02050000</td>
<td>Beta-Adrenoceptor Blocking Drugs/Hypertension And Heart Failure</td>
</tr>
<tr>
<td>02040000/02060200</td>
<td>Beta-Adrenoceptor Blocking Drugs/Calcium-Channel Blockers</td>
</tr>
<tr>
<td>02040000/02090000</td>
<td>Beta-adrenoceptor Blocking Drugs/Antiplatelet Drugs</td>
</tr>
<tr>
<td>02040000/04070402</td>
<td>Beta-Adrenoceptor Blocking Drugs/Prophylaxis Of Migraine/Drugs Fo</td>
</tr>
<tr>
<td>02050200/04070402</td>
<td>Centrally Acting Antihypertensive Drugs/Prophylaxis Of Migraine/O</td>
</tr>
<tr>
<td>02050502/02050600</td>
<td>Angiotensin-ii Receptor Antagonists/Other Antihypertensives</td>
</tr>
<tr>
<td>04070402/06040101</td>
<td>Prophylaxis Of Migraine/Oestrogens And Hrt</td>
</tr>
</tbody>
</table>
**Supplementary Table 2.** Distribution of beta-blocker prescriptions among patients with a first-ever and ever prescription

<table>
<thead>
<tr>
<th>Type of beta-blocker</th>
<th>Number of patients with first-ever prescription (%)&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Number of patients with ever prescription (%)&lt;sup&gt;b&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Propranolol 40mg</td>
<td>118,129 (23.9)</td>
<td>221,444 (16.0)</td>
</tr>
<tr>
<td>Propranolol 80mg</td>
<td>94,042 (19.0)</td>
<td>195,533 (14.0)</td>
</tr>
<tr>
<td>Propranolol 10mg</td>
<td>91,899 (18.6)</td>
<td>175,639 (12.7)</td>
</tr>
<tr>
<td>Atenolol 50mg</td>
<td>61,051 (12.4)</td>
<td>390,754 (28.2)</td>
</tr>
<tr>
<td>Atenolol 25mg</td>
<td>44,143 (8.9)</td>
<td>289,576 (20.9)</td>
</tr>
<tr>
<td>Bisoprolol 2.5mg</td>
<td>25,367 (5.1)</td>
<td>248,670 (18.0)</td>
</tr>
<tr>
<td>Bisoprolol 1.25mg</td>
<td>15,345 (3.1)</td>
<td>164,137 (11.8)</td>
</tr>
<tr>
<td>Bisoprolol 5mg</td>
<td>9,035 (1.8)</td>
<td>165,388 (12.0)</td>
</tr>
<tr>
<td>Metoprolol 50mg</td>
<td>5,149 (1.0)</td>
<td>38,252 (2.8)</td>
</tr>
<tr>
<td>Sotalol 40mg</td>
<td>4,802 (1.0)</td>
<td>28,457 (2.1)</td>
</tr>
<tr>
<td>Atenolol 100mg</td>
<td>3,758 (0.8)</td>
<td>112,497 (8.1)</td>
</tr>
<tr>
<td>Labetalol 100mg</td>
<td>4,168 (0.8)</td>
<td>11,279 (0.8)</td>
</tr>
<tr>
<td>Labetalol 200mg</td>
<td>3,143 (0.6)</td>
<td>8,860 (0.6)</td>
</tr>
<tr>
<td>Propranolol 160mg</td>
<td>957 (0.2)</td>
<td>19,425 (1.4)</td>
</tr>
<tr>
<td>Sotalol 80mg</td>
<td>1,443 (0.3)</td>
<td>17,439 (1.3)</td>
</tr>
<tr>
<td>Nebivolol 5mg</td>
<td>1,130 (0.2)</td>
<td>18,169 (1.3)</td>
</tr>
<tr>
<td>Bisoprolol 10mg</td>
<td>876 (0.2)</td>
<td>58,102 (4.2)</td>
</tr>
</tbody>
</table>

<sup>a</sup> Other agents included carvedilol, celiprolol, oxprenolol, timolol, acebutolol, pindolol (n=9,886, 2.0%).

<sup>b</sup> Non mutually exclusive categories.
**Supplementary Table 3.** Baseline characteristics of primary care patients with a first-ever antihypertensive drug prescription between January 1, 1988 and December 31, 1999

<table>
<thead>
<tr>
<th>Smoking status</th>
<th>Male, n (%)</th>
<th>Diastolic</th>
<th>Systolic</th>
<th>Hypertension b</th>
<th>Medical history, n (%) c</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mean age, years (SD)</td>
<td>62.4 (15.8)</td>
<td>69.8 (13.3)</td>
<td>59.3 (12.7)</td>
<td>64.2 (12.9)</td>
<td>90.0 (13.3)</td>
</tr>
<tr>
<td>Mean BMI, kg/m² (SD)</td>
<td>27.0 (5.1)</td>
<td>28.0 (5.2)</td>
<td>27.6 (5.0)</td>
<td>22.8 (4.7)</td>
<td>110 (18.7)</td>
</tr>
<tr>
<td>Diastolic</td>
<td>91.0 (13.3)</td>
<td>94.2 (12.9)</td>
<td>94.1 (11.9)</td>
<td>83.4 (13.5)</td>
<td>121 (13.1)</td>
</tr>
<tr>
<td>Hypertension b</td>
<td>26,714 (55.8)</td>
<td>9,865 (71.4)</td>
<td>424 (72.1)</td>
<td>21,827 (27.1)</td>
<td>9,906 (44.2)</td>
</tr>
<tr>
<td>Heart failure</td>
<td>773 (1.6)</td>
<td>552 (4.0)</td>
<td>8 (1.4)</td>
<td>87 (0.1)</td>
<td>101 (0.5)</td>
</tr>
<tr>
<td>Coronary heart disease d</td>
<td>5,462 (11.4)</td>
<td>2,788 (20.2)</td>
<td>78 (13.3)</td>
<td>12,592 (15.6)</td>
<td>7,624 (34.0)</td>
</tr>
<tr>
<td>Peripheral vascular disease</td>
<td>1,098 (2.3)</td>
<td>475 (3.4)</td>
<td>14 (2.4)</td>
<td>848 (1.1)</td>
<td>1,770 (7.9)</td>
</tr>
<tr>
<td>Stroke</td>
<td>1,274 (2.7)</td>
<td>392 (2.8)</td>
<td>16 (2.7)</td>
<td>718 (0.9)</td>
<td>811 (3.6)</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>1,038 (2.2)</td>
<td>543 (3.9)</td>
<td>19 (3.2)</td>
<td>2,422 (3.0)</td>
<td>1,128 (5.0)</td>
</tr>
<tr>
<td>Stable angina</td>
<td>761 (1.6)</td>
<td>427 (3.1)</td>
<td>14 (2.4)</td>
<td>1,273 (1.6)</td>
<td>622 (2.8)</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>1,261 (2.6)</td>
<td>743 (5.4)</td>
<td>19 (3.2)</td>
<td>5,624 (7.0)</td>
<td>4,568 (20.4)</td>
</tr>
<tr>
<td>Diabetes</td>
<td>90 (0.2)</td>
<td>96 (0.7)</td>
<td>58 (0.8)</td>
<td>172 (0.2)</td>
<td>125 (0.6)</td>
</tr>
<tr>
<td>Chronic kidney disease</td>
<td>517 (1.1)</td>
<td>458 (3.2)</td>
<td>121 (2.2)</td>
<td>2,214 (5.5)</td>
<td>240 (1.9)</td>
</tr>
</tbody>
</table>

Abbreviations: ACE inhibitors, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; CCBs, calcium channel blockers; SD, standard deviation; BMI, body mass index

a Other antihypertensive drugs.

b Defined as a recorded diagnosis of hypertension or at least three elevated systolic (≥120) or diastolic (≥90) blood pressure readings in the year before cohort entry.

c Non mutually exclusive categories.

d Includes stable ischemic heart disease (chronic coronary syndrome), carotid artery disease (carotid stenosis), and peripheral artery disease.

e Cell <5 patients are suppressed as per Clinical Practice Research Datalink policy.
Supplementary Table 4. Baseline characteristics of primary care patients with a first-ever antihypertensive drug prescription between January 1, 2000 and December 31, 2009

<table>
<thead>
<tr>
<th></th>
<th>Thiazide diuretics</th>
<th>ACE inhibitors</th>
<th>ARBs</th>
<th>Beta-blockers</th>
<th>CCBs</th>
<th>Other diuretics</th>
<th>Other*</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>137,473 (20.1)</td>
<td>127,627 (18.6)</td>
<td>12,566 (1.8)</td>
<td>228,382 (33.3)</td>
<td>78,206 (11.4)</td>
<td>75,147 (11.0)</td>
<td>26,194 (3.8)</td>
<td>685,595</td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>54,697 (39.8)</td>
<td>80,708 (63.2)</td>
<td>7,673 (61.1)</td>
<td>98,018 (42.9)</td>
<td>41,642 (53.3)</td>
<td>28,596 (38.1)</td>
<td>2,552 (9.7)</td>
<td>313,886 (45.8)</td>
</tr>
<tr>
<td>Mean age, years (SD)</td>
<td>63.4 (14.0)</td>
<td>57.8 (13.2)</td>
<td>57.7 (13.3)</td>
<td>47.8 (16.6)</td>
<td>61.7 (14.5)</td>
<td>65.8 (17.9)</td>
<td>53.2 (11.0)</td>
<td>56.7 (16.7)</td>
</tr>
<tr>
<td>Mean BMI, kg/m² (SD)</td>
<td>27.7 (5.4)</td>
<td>29.1 (5.8)</td>
<td>28.7 (5.6)</td>
<td>26.2 (5.2)</td>
<td>27.2 (5.3)</td>
<td>27.5 (6.6)</td>
<td>26.6 (5.2)</td>
<td>27.4 (5.7)</td>
</tr>
</tbody>
</table>

Smoking status

|                          | Current         | 40,738 (29.6) | 33,921 (26.6) | 3,219 (25.6) | 81,013 (35.5) | 21,753 (27.8) | 23,869 (31.8) | 9,061 (34.6) | 213,574 (31.2) |
|                          | Never           | 61,901 (45.8) | 58,448 (45.8) | 5,889 (46.9) | 96,980 (42.5) | 34,710 (44.4) | 29,333 (39.0) | 11,696 (44.7) | 298,957 (43.6) |
|                          | Past            | 24,672 (18.0) | 30,762 (24.1) | 2,604 (20.7) | 32,253 (14.1) | 17,890 (22.9) | 13,805 (18.4) | 3,359 (15.1)  | 125,945 (18.4) |
|                          | Unknown         | 10,162 (7.4)  | 4,496 (3.5)   | 854 (6.8)     | 18,136 (7.9)  | 3,853 (4.9)   | 8,140 (10.8)  | 1,478 (5.6)   | 47,119 (6.8)   |

Mean blood pressure, mmHg (SD)

|                          | Systolic       | 162.5 (21.5) | 157.0 (20.2) | 159.3 (20.4) | 137.0 (23.4) | 158.0 (24.1) | 136.3 (18.8) | 133.2 (19.8) | 148.6 (24.8)    |
|                          | Diastolic      | 91.9 (11.7)  | 91.8 (12.4)   | 93.0 (11.9)   | 82.3 (12.8)   | 89.9 (13.1)   | 79.1 (9.9)    | 80.4 (10.8)   | 86.7 (13.2)     |

Hypertension b

|                          | Total          | 105,944 (77.1) | 96,472 (75.6) | 9,977 (79.4) | 64,283 (28.1) | 52,662 (67.3) | 10,836 (14.4) | 6,087 (23.2) | 346,261 (50.5) |

Medical history, n (%) c

|                          | Heart failure  | 314 (0.2)     | 1,491 (1.2)   | 57 (0.5)      | 532 (0.2)      | 162 (0.2)      | 3,058 (4.1)   | 32 (0.1)      | 5,646 (0.8)    |
| Coronary heart disease d | 12,698 (9.2)   | 14,997 (11.8) | 1,075 (8.6)   | 24,108 (10.6) | 10,374 (13.3)  | 7,777 (10.3)   | 1,124 (4.3)   | 72,153 (10.5) |
| Peripheral vascular disease | 2,771 (2.0) | 3,435 (2.7)   | 234 (1.9)     | 1,948 (0.9)   | 2,952 (3.8)    | 1,655 (5.3)    | 365 (0.5)     | 14,208 (2.1)  |
| Stroke                   | 3,253 (2.4)    | 5,181 (4.1)   | 264 (2.1)     | 2,016 (0.9)   | 1,798 (2.3)    | 2,645 (3.5)    | 208 (0.8)     | 15,365 (2.2)  |
| Arrhythmias              | 2,408 (1.8)    | 3,199 (2.5)   | 272 (2.2)     | 1,125 (5.3)   | 3,125 (4.0)    | 4,509 (6.0)    | 196 (0.7)     | 25,834 (3.8)  |
| Atrial fibrillation      | 1,094 (1.2)    | 2,466 (1.9)   | 191 (1.5)     | 8,618 (3.8)   | 2,060 (2.6)    | 3,940 (5.2)    | 96 (0.4)      | 19,065 (2.8)  |
| Stable angina            | 1,882 (1.4)    | 3,164 (2.5)   | 204 (1.6)     | 10,202 (4.5)  | 3,366 (4.3)    | 1,833 (2.4)    | 152 (0.6)     | 20,803 (3.0)  |
| Myocardial infarction    | 801 (0.6)      | 3,762 (3.0)   | 171 (1.4)     | 5,456 (2.4)   | 1,066 (1.4)    | 1,363 (1.8)    | 52 (0.2)      | 12,671 (1.8)  |
| Diabetes                 | 15,296 (11.1)  | 44,128 (34.6) | 3,076 (24.5)  | 23,804 (10.4) | 10,267 (13.1)  | 9,142 (12.2)   | 3,392 (12.9)  | 109,105 (15.9) |
| Chronic kidney disease   | 1,141 (0.8)    | 6,190 (4.9)   | 408 (3.2)     | 1,522 (0.7)   | 1,764 (2.3)    | 1,569 (2.1)    | 175 (0.7)     | 12,769 (1.9)  |

Abbreviations: ACE inhibitors, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; CCBs, calcium channel blockers; SD, standard deviation; BMI, body mass index
* Other antihypertensive drugs.
b Defined as a recorded diagnosis of hypertension or at least three elevated systolic (≥140) or diastolic (≥90) blood pressure readings in the year before cohort entry.
^ Non mutually exclusive categories.
± Includes stable ischemic heart disease (chronic coronary syndrome), carotid artery disease (carotid stenosis), and peripheral artery disease.
Supplementary Table 5. Baseline characteristics of primary care patients with a first-ever antihypertensive drug prescription between January 1, 2010 and December 31, 2018

<table>
<thead>
<tr>
<th>Medication Class</th>
<th>Total</th>
<th>Male, n (%)</th>
<th>Mean age, years (SD)</th>
<th>Mean BMI, kg/m² (SD)</th>
<th>Smoking status</th>
<th>Mean blood pressure, mmHg (SD)</th>
<th>Medical history, n (%)</th>
<th>Other diuretics</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Thiazide diuretics</td>
<td>ACE inhibitors</td>
<td>ARBs</td>
<td>Beta-blockers</td>
<td>CCBs</td>
<td>Other diuretics</td>
<td>Total</td>
<td></td>
</tr>
<tr>
<td>Total</td>
<td>17,509 (3.8)</td>
<td>96,489 (21.2)</td>
<td>4,692 (1.0)</td>
<td>185,458 (40.7)</td>
<td>95,867 (21.0)</td>
<td>42,476 (9.3)</td>
<td>13,551 (3.0)</td>
<td>456,042 (45.2)</td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>6,315 (36.1)</td>
<td>60,378 (62.6)</td>
<td>2,707 (57.7)</td>
<td>69,596 (37.5)</td>
<td>50,211 (32.4)</td>
<td>16,171 (38.1)</td>
<td>16,171 (38.1)</td>
<td>205,900 (45.2)</td>
</tr>
<tr>
<td>Mean age, years (SD)</td>
<td>63.9 (14.5)</td>
<td>54.5 (12.3)</td>
<td>54.8 (13.5)</td>
<td>42.5 (16.7)</td>
<td>61.4 (13.7)</td>
<td>63.8 (17.8)</td>
<td>63.8 (17.8)</td>
<td>51.4 (8.6)</td>
</tr>
<tr>
<td>Mean BMI, kg/m² (SD)</td>
<td>28.5 (6.0)</td>
<td>30.0 (6.2)</td>
<td>29.4 (6.2)</td>
<td>26.5 (5.8)</td>
<td>27.9 (5.5)</td>
<td>28.7 (7.6)</td>
<td>28.7 (7.6)</td>
<td>27.3 (5.6)</td>
</tr>
<tr>
<td>Smoking status</td>
<td>Current</td>
<td>3,354 (19.2)</td>
<td>21,049 (21.8)</td>
<td>833 (17.8)</td>
<td>51,492 (27.8)</td>
<td>19,221 (20.1)</td>
<td>10,550 (24.8)</td>
<td>3,920 (28.9)</td>
</tr>
<tr>
<td></td>
<td>Never</td>
<td>9,296 (53.1)</td>
<td>49,692 (51.5)</td>
<td>2,650 (56.5)</td>
<td>94,849 (51.2)</td>
<td>49,544 (51.7)</td>
<td>19,449 (45.8)</td>
<td>6,649 (49.1)</td>
</tr>
<tr>
<td></td>
<td>Past</td>
<td>4,762 (27.2)</td>
<td>25,361 (26.3)</td>
<td>1,177 (25.1)</td>
<td>36,574 (19.7)</td>
<td>26,511 (27.7)</td>
<td>12,162 (28.6)</td>
<td>2,943 (21.7)</td>
</tr>
<tr>
<td></td>
<td>Unknown</td>
<td>97 (0.6)</td>
<td>387 (0.4)</td>
<td>32 (0.7)</td>
<td>2,543 (14.4)</td>
<td>591 (0.6)</td>
<td>315 (0.7)</td>
<td>39 (0.3)</td>
</tr>
<tr>
<td>Mean blood pressure, mmHg (SD)</td>
<td>Systolic</td>
<td>154.6 (22.1)</td>
<td>155.4 (19.1)</td>
<td>150.7 (20.8)</td>
<td>127.0 (16.5)</td>
<td>157.9 (22.5)</td>
<td>131.7 (16.6)</td>
<td>127.9 (15.6)</td>
</tr>
<tr>
<td></td>
<td>Diastolic</td>
<td>87.5 (11.9)</td>
<td>92.8 (12.0)</td>
<td>89.7 (12.4)</td>
<td>77.7 (10.3)</td>
<td>90.2 (12.7)</td>
<td>77.5 (9.6)</td>
<td>78.4 (9.6)</td>
</tr>
<tr>
<td>Hypertension b</td>
<td>11,872 (67.8)</td>
<td>75,415 (78.2)</td>
<td>3,267 (69.6)</td>
<td>26,942 (14.5)</td>
<td>70,794 (73.8)</td>
<td>7,125 (16.8)</td>
<td>2,418 (17.8)</td>
<td>197,833 (43.4)</td>
</tr>
<tr>
<td>Medical history, n (%) c</td>
<td>Heart failure</td>
<td>20 (0.1)</td>
<td>981 (1.0)</td>
<td>35 (0.7)</td>
<td>615 (0.3)</td>
<td>140 (0.1)</td>
<td>844 (2.0)</td>
<td>6 (0)</td>
</tr>
<tr>
<td></td>
<td>Coronary heart disease d</td>
<td>1,150 (6.6)</td>
<td>7,812 (8.1)</td>
<td>304 (6.5)</td>
<td>9,543 (5.1)</td>
<td>6,901 (7.2)</td>
<td>3,404 (8.0)</td>
<td>306 (2.3)</td>
</tr>
<tr>
<td></td>
<td>Peripheral vascular disease e</td>
<td>364 (2.1)</td>
<td>1,823 (1.9)</td>
<td>68 (1.4)</td>
<td>1,081 (0.6)</td>
<td>2,191 (2.3)</td>
<td>1,305 (3.1)</td>
<td>73 (0.5)</td>
</tr>
<tr>
<td></td>
<td>Stroke</td>
<td>563 (3.2)</td>
<td>3,004 (3.1)</td>
<td>116 (2.5)</td>
<td>1,661 (0.9)</td>
<td>2,470 (2.6)</td>
<td>1,537 (3.6)</td>
<td>87 (0.6)</td>
</tr>
<tr>
<td></td>
<td>Atrial fibrillation</td>
<td>322 (1.8)</td>
<td>1,601 (1.7)</td>
<td>88 (1.9)</td>
<td>12,895 (7.0)</td>
<td>2,503 (2.6)</td>
<td>1,983 (4.7)</td>
<td>70 (0.5)</td>
</tr>
<tr>
<td></td>
<td>Stable angina</td>
<td>103 (0.6)</td>
<td>1,326 (1.4)</td>
<td>56 (1.2)</td>
<td>3,487 (1.9)</td>
<td>978 (1.0)</td>
<td>580 (1.4)</td>
<td>20 (0.1)</td>
</tr>
<tr>
<td></td>
<td>Myocardial infarction</td>
<td>49 (0.3)</td>
<td>2,031 (2.1)</td>
<td>83 (1.8)</td>
<td>2,210 (1.2)</td>
<td>358 (0.4)</td>
<td>474 (1.1)</td>
<td>520 (1.1)</td>
</tr>
<tr>
<td></td>
<td>Diabetes</td>
<td>3,212 (18.3)</td>
<td>32,019 (33.2)</td>
<td>1,326 (28.3)</td>
<td>30,203 (16.2)</td>
<td>19,256 (20.1)</td>
<td>8,195 (19.3)</td>
<td>3,072 (22.7)</td>
</tr>
<tr>
<td></td>
<td>Chronic kidney disease</td>
<td>758 (4.3)</td>
<td>5,236 (5.4)</td>
<td>275 (5.9)</td>
<td>3,013 (1.6)</td>
<td>4,129 (4.3)</td>
<td>2,755 (6.5)</td>
<td>254 (1.9)</td>
</tr>
</tbody>
</table>

Abbreviations: ACE inhibitors, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; CCBs, calcium channel blockers; SD, standard deviation; BMI, body mass index

*a* Other antihypertensive drugs

*b* Defined as a recorded diagnosis of hypertension or at least three elevated systolic (>140) or diastolic (>90) blood pressure readings in the year before cohort entry.

*c* Non mutually exclusive categories.

*d* Includes stable ischemic heart disease (chronic coronary syndrome), carotid artery disease (carotid stenosis), and peripheral artery disease.

*e* Cell <5 patients are suppressed as per Clinical Practice Research Datalink policy.
## Supplementary Table 6. Baseline characteristics of hypertensive primary care patients with a first-line antihypertensive drug prescription before January 1, 2007

<table>
<thead>
<tr>
<th></th>
<th>Thiazide diuretics</th>
<th>ACE inhibitors</th>
<th>ARBs</th>
<th>Beta-blockers</th>
<th>CCBs</th>
<th>Other diuretics</th>
<th>Other†</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total</td>
<td>116,749 (36.8)</td>
<td>60,929 (19.2)</td>
<td>7,922 (2.5)</td>
<td>74,917 (23.6)</td>
<td>37,230 (11.7)</td>
<td>11,907 (3.8)</td>
<td>7,556 (2.4)</td>
<td>317,210</td>
</tr>
<tr>
<td>Male, n (%)</td>
<td>47,592 (40.8)</td>
<td>38,033 (62.4)</td>
<td>4,851 (61.2)</td>
<td>36,452 (48.7)</td>
<td>20,299 (54.5)</td>
<td>4,471 (37.6)</td>
<td>1,949 (25.8)</td>
<td>153,647 (48.4)</td>
</tr>
<tr>
<td>Mean age, years (SD)</td>
<td>63.8 (12.9)</td>
<td>58.1 (12.7)</td>
<td>57.7 (12.8)</td>
<td>55.4 (14.0)</td>
<td>63.2 (13.0)</td>
<td>67.3 (16.2)</td>
<td>57.8 (14.2)</td>
<td>60.5 (13.8)</td>
</tr>
<tr>
<td>Mean body mass index, kg/m² (SD)</td>
<td>27.6 (5.2)</td>
<td>29.0 (5.6)</td>
<td>28.7 (5.5)</td>
<td>27.4 (5.1)</td>
<td>27.6 (5.2)</td>
<td>28.1 (6.4)</td>
<td>27.7 (5.5)</td>
<td>27.9 (5.4)</td>
</tr>
<tr>
<td><strong>Smoking status</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current</td>
<td>34,296 (29.4)</td>
<td>17,348 (28.5)</td>
<td>2,151 (27.2)</td>
<td>24,422 (32.6)</td>
<td>10,322 (27.7)</td>
<td>3,437 (28.9)</td>
<td>2,034 (26.9)</td>
<td>94,010 (29.6)</td>
</tr>
<tr>
<td>Never</td>
<td>54,632 (46.8)</td>
<td>27,748 (45.5)</td>
<td>3,710 (46.8)</td>
<td>34,271 (45.8)</td>
<td>16,630 (44.7)</td>
<td>5,188 (43.6)</td>
<td>3,607 (47.7)</td>
<td>145,786 (46.0)</td>
</tr>
<tr>
<td>Past</td>
<td>17,776 (15.2)</td>
<td>12,132 (19.9)</td>
<td>1,497 (18.9)</td>
<td>9,579 (12.8)</td>
<td>7,009 (18.8)</td>
<td>1,905 (16.0)</td>
<td>875 (11.6)</td>
<td>50,773 (16.0)</td>
</tr>
<tr>
<td>Unknown</td>
<td>10,045 (8.6)</td>
<td>3,701 (6.1)</td>
<td>564 (7.1)</td>
<td>6,645 (8.9)</td>
<td>3,269 (8.8)</td>
<td>1,377 (11.6)</td>
<td>1,040 (13.8)</td>
<td>26,641 (8.4)</td>
</tr>
<tr>
<td><strong>Mean blood pressure, mmHg (SD)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic</td>
<td>168.7 (16.9)</td>
<td>163.5 (17.2)</td>
<td>164.1 (17.5)</td>
<td>164.8 (18.9)</td>
<td>168.2 (18.2)</td>
<td>153.4 (17.5)</td>
<td>160.0 (20.8)</td>
<td>166.2 (17.9)</td>
</tr>
<tr>
<td>Diastolic</td>
<td>95.1 (10.0)</td>
<td>94.8 (10.9)</td>
<td>95.4 (10.5)</td>
<td>96.1 (10.9)</td>
<td>94.3 (11.3)</td>
<td>85.7 (10.2)</td>
<td>93.0 (11.2)</td>
<td>94.9 (10.6)</td>
</tr>
<tr>
<td><strong>Medical history, n (%)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heart failure</td>
<td>262 (0.2)</td>
<td>493 (0.8)</td>
<td>21 (0.3)</td>
<td>122 (0.2)</td>
<td>103 (0.3)</td>
<td>1,110 (9.3)</td>
<td>41 (0.5)</td>
<td>2,152 (0.7)</td>
</tr>
<tr>
<td>Coronary heart disease†</td>
<td>13,123 (11.2)</td>
<td>7,359 (12.1)</td>
<td>702 (8.9)</td>
<td>10,177 (14.3)</td>
<td>6,047 (16.2)</td>
<td>2,267 (19.0)</td>
<td>672 (8.9)</td>
<td>20,887 (6.6)</td>
</tr>
<tr>
<td>Peripheral vascular disease</td>
<td>2,431 (2.1)</td>
<td>1,737 (2.9)</td>
<td>141 (1.8)</td>
<td>874 (1.2)</td>
<td>1,739 (4.7)</td>
<td>574 (4.8)</td>
<td>102 (1.3)</td>
<td>7,598 (2.4)</td>
</tr>
<tr>
<td>Stroke</td>
<td>2,597 (2.2)</td>
<td>1,921 (3.2)</td>
<td>140 (1.8)</td>
<td>1,067 (1.4)</td>
<td>1,133 (3.0)</td>
<td>612 (5.1)</td>
<td>125 (1.7)</td>
<td>7,595 (2.4)</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>1,395 (1.2)</td>
<td>984 (1.6)</td>
<td>103 (1.3)</td>
<td>1,650 (2.2)</td>
<td>765 (2.1)</td>
<td>882 (7.4)</td>
<td>83 (1.1)</td>
<td>5,862 (1.8)</td>
</tr>
<tr>
<td>Stable angina</td>
<td>2,093 (1.8)</td>
<td>1,583 (2.6)</td>
<td>126 (1.6)</td>
<td>3,933 (5.2)</td>
<td>2,137 (5.7)</td>
<td>718 (6.0)</td>
<td>139 (1.8)</td>
<td>10,729 (3.4)</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>799 (0.7)</td>
<td>1,203 (2.0)</td>
<td>76 (1.0)</td>
<td>1,908 (2.5)</td>
<td>724 (1.9)</td>
<td>446 (3.7)</td>
<td>53 (0.7)</td>
<td>5,209 (1.6)</td>
</tr>
<tr>
<td>Diabetes</td>
<td>12,048 (10.5)</td>
<td>22,004 (36.1)</td>
<td>1,773 (22.4)</td>
<td>9,258 (12.8)</td>
<td>5,149 (13.8)</td>
<td>2,240 (18.8)</td>
<td>1,090 (14.4)</td>
<td>53,562 (16.9)</td>
</tr>
<tr>
<td>Chronic kidney disease</td>
<td>356 (0.3)</td>
<td>937 (1.5)</td>
<td>98 (1.2)</td>
<td>294 (0.4)</td>
<td>392 (1.1)</td>
<td>97 (0.8)</td>
<td>32 (0.4)</td>
<td>2,206 (0.7)</td>
</tr>
</tbody>
</table>

Abbreviations: ACE inhibitors, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; CCBs, calcium channel blockers; SD, standard deviation; BMI, body mass index
† Other antihypertensive drugs.
‡ Non mutually exclusive categories.
§ Includes stable ischemic heart disease (chronic coronary syndrome), carotid artery disease (carotid stenosis), and peripheral artery disease.
**Supplementary Table 7.** Baseline characteristics of hypertensive primary care patients with a first-line antihypertensive drug prescription after January 1, 2007

<table>
<thead>
<tr>
<th></th>
<th>Thiazide diuretics</th>
<th>ACE inhibitors</th>
<th>ARBs</th>
<th>Beta-blockers</th>
<th>CCBs</th>
<th>Other diuretics</th>
<th>Other a</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total</strong></td>
<td>27,781 (9.2)</td>
<td>120,823 (39.9)</td>
<td>5,746 (1.9)</td>
<td>38,135 (12.6)</td>
<td>96,132 (31.8)</td>
<td>10,325 (3.4)</td>
<td>3,832 (1.3)</td>
<td>302,774</td>
</tr>
<tr>
<td><strong>Male, n (%)</strong></td>
<td>11,172 (40.2)</td>
<td>74,394 (61.6)</td>
<td>3,448 (60.0)</td>
<td>13,662 (35.8)</td>
<td>52,042 (54.1)</td>
<td>3,751 (36.3)</td>
<td>368 (9.6)</td>
<td>158,839 (52.5)</td>
</tr>
<tr>
<td><strong>Mean age, years (SD)</strong></td>
<td>66.2 (12.4)</td>
<td>54.4 (11.9)</td>
<td>55.8 (12.7)</td>
<td>49.7 (16.3)</td>
<td>63.8 (11.9)</td>
<td>66.1 (17.2)</td>
<td>51.1 (10.6)</td>
<td>58.1 (14.0)</td>
</tr>
<tr>
<td><strong>Mean body mass index, kg/m^2 (SD)</strong></td>
<td>28.1 (5.6)</td>
<td>30.0 (6.1)</td>
<td>29.3 (6.0)</td>
<td>27.6 (5.9)</td>
<td>28.2 (5.4)</td>
<td>29.4 (7.7)</td>
<td>28.4 (6.0)</td>
<td>28.9 (6.0)</td>
</tr>
<tr>
<td><strong>Smoking status</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current</td>
<td>5,037 (18.1)</td>
<td>25,466 (21.1)</td>
<td>1,102 (19.2)</td>
<td>8,238 (21.6)</td>
<td>18,427 (19.2)</td>
<td>2,200 (21.3)</td>
<td>950 (24.8)</td>
<td>61,420 (20.3)</td>
</tr>
<tr>
<td>Never</td>
<td>14,713 (53.0)</td>
<td>62,859 (52.0)</td>
<td>3,080 (53.6)</td>
<td>20,641 (54.1)</td>
<td>49,482 (51.5)</td>
<td>4,945 (47.9)</td>
<td>2,011 (52.5)</td>
<td>157,731 (52.1)</td>
</tr>
<tr>
<td>Past</td>
<td>7,844 (28.2)</td>
<td>31,884 (26.4)</td>
<td>1,505 (26.2)</td>
<td>9,072 (23.8)</td>
<td>27,632 (28.7)</td>
<td>3,118 (30.2)</td>
<td>858 (22.4)</td>
<td>81,913 (27.1)</td>
</tr>
<tr>
<td>Unknown</td>
<td>187 (0.7)</td>
<td>614 (0.5)</td>
<td>59 (1.0)</td>
<td>184 (0.5)</td>
<td>591 (0.6)</td>
<td>62 (0.6)</td>
<td>13 (0.3)</td>
<td>1,710 (0.6)</td>
</tr>
<tr>
<td><strong>Mean blood pressure, mmHg (SD)</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Systolic</td>
<td>164.4 (15.3)</td>
<td>160.0 (15.6)</td>
<td>160.3 (16.7)</td>
<td>150.8 (17.0)</td>
<td>164.6 (16.4)</td>
<td>147.7 (15.1)</td>
<td>148.8 (17.0)</td>
<td>161.1 (16.5)</td>
</tr>
<tr>
<td>Diastolic</td>
<td>91.4 (10.3)</td>
<td>95.2 (10.1)</td>
<td>94.2 (10.2)</td>
<td>89.4 (11.0)</td>
<td>92.9 (10.8)</td>
<td>83.2 (9.8)</td>
<td>89.4 (10.5)</td>
<td>93.4 (10.7)</td>
</tr>
<tr>
<td><strong>Medical history, n (%)</strong> b</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heart failure</td>
<td>23 (0.1)</td>
<td>416 (0.3)</td>
<td>21 (0.4)</td>
<td>187 (0.5)</td>
<td>15 (0.0)</td>
<td>278 (2.7)</td>
<td>S d</td>
<td>1,042 (0.3)</td>
</tr>
<tr>
<td>Coronary heart disease c</td>
<td>2,125 (7.6)</td>
<td>7,822 (6.5)</td>
<td>349 (6.1)</td>
<td>3,479 (9.1)</td>
<td>7,071 (7.4)</td>
<td>1,239 (12.0)</td>
<td>155 (4.0)</td>
<td>22,240 (7.3)</td>
</tr>
<tr>
<td>Peripheral vascular disease</td>
<td>576 (2.1)</td>
<td>1,829 (1.5)</td>
<td>86 (1.5)</td>
<td>345 (0.9)</td>
<td>2,090 (2.2)</td>
<td>374 (3.6)</td>
<td>25 (0.7)</td>
<td>5,325 (1.8)</td>
</tr>
<tr>
<td>Stroke</td>
<td>688 (2.5)</td>
<td>2,512 (2.1)</td>
<td>103 (1.8)</td>
<td>543 (1.4)</td>
<td>1,997 (2.1)</td>
<td>559 (5.4)</td>
<td>32 (0.9)</td>
<td>6,434 (2.1)</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>495 (1.8)</td>
<td>1,557 (1.3)</td>
<td>93 (1.6)</td>
<td>3,402 (8.9)</td>
<td>1,796 (1.9)</td>
<td>687 (6.7)</td>
<td>22 (0.6)</td>
<td>8,052 (2.7)</td>
</tr>
<tr>
<td>Arrhythmias</td>
<td>328 (1.2)</td>
<td>938 (0.8)</td>
<td>66 (1.1)</td>
<td>2,619 (6.9)</td>
<td>1,146 (1.2)</td>
<td>577 (5.6)</td>
<td>8 (0.2)</td>
<td>5,682 (1.9)</td>
</tr>
<tr>
<td>Stable angina</td>
<td>206 (0.7)</td>
<td>843 (0.7)</td>
<td>40 (0.7)</td>
<td>1,252 (3.3)</td>
<td>778 (0.8)</td>
<td>236 (2.3)</td>
<td>10 (0.3)</td>
<td>3,355 (1.1)</td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>81 (0.3)</td>
<td>762 (0.6)</td>
<td>39 (0.7)</td>
<td>575 (1.5)</td>
<td>291 (0.3)</td>
<td>156 (1.5)</td>
<td>S d</td>
<td>1,906 (0.6)</td>
</tr>
<tr>
<td>Diabetes</td>
<td>4,487 (16.2)</td>
<td>35,055 (29.0)</td>
<td>1,427 (24.8)</td>
<td>10,847 (28.4)</td>
<td>18,746 (19.5)</td>
<td>2,812 (27.2)</td>
<td>1,222 (31.9)</td>
<td>74,596 (24.6)</td>
</tr>
<tr>
<td>Chronic kidney disease</td>
<td>1,134 (4.1)</td>
<td>6,195 (5.1)</td>
<td>335 (5.8)</td>
<td>1,097 (2.9)</td>
<td>4,237 (4.4)</td>
<td>892 (8.6)</td>
<td>91 (2.4)</td>
<td>14,071 (4.6)</td>
</tr>
</tbody>
</table>

Abbreviations: ACE inhibitors, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; CCBs, calcium channel blockers; SD, standard deviation; BMI, body mass index

a Other antihypertensive drugs.

b Non mutually exclusive categories.

c Includes stable ischemic heart disease (chronic coronary syndrome), carotid artery disease (carotid stenosis), and peripheral artery disease.

d Cell <5 patients are suppressed as per Clinical Practice Research Datalink policy.
**Supplementary Table 8.** Percentage of patients with switches or add-ons and median number of days of prescription before treatment change

<table>
<thead>
<tr>
<th>Number of switches or add-ons</th>
<th>Pre-2007 cohort</th>
<th>Post-2007 cohort</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n (%)</td>
<td>Median number of days of prescription (interquartile range)</td>
</tr>
<tr>
<td>0</td>
<td>65,323 (20.6)</td>
<td>801 (64-2678)</td>
</tr>
<tr>
<td>1</td>
<td>71,726 (22.6)</td>
<td>1232 (252-2849)</td>
</tr>
<tr>
<td>2</td>
<td>71,614 (22.6)</td>
<td>1188 (250-2676)</td>
</tr>
<tr>
<td>3</td>
<td>56,959 (18.0)</td>
<td>1048 (191-2470)</td>
</tr>
<tr>
<td>4</td>
<td>33,559 (11.0)</td>
<td>847 (132-2138)</td>
</tr>
<tr>
<td>≥5</td>
<td>18,029 (5.7)</td>
<td>710 (102-1922)</td>
</tr>
</tbody>
</table>

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance on the material contained in this supplement which is supplied by the author(s).
Supplementary Figure 1. Percentage of primary care patients with antihypertensive drug prescriptions, stratified by treatment intensity (number of classes prescribed)
Supplementary Figure 2AB. Percentage of male and female primary care patients with antihypertensive drug prescriptions, stratified by treatment intensity (number of classes prescribed)
Supplementary Figure 3A-D. Percentage of primary care patients with antihypertensive drug prescriptions for each age group, stratified by treatment intensity (number of classes prescribed)
Supplementary Figure 4A-G. Period prevalence of primary care patients for each antihypertensive drug class, stratified by sex and age
G. Other antihypertensives

Supplemental material placed on this supplemental material which has been supplied by the author(s)

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance

BMJ Open

doi: 10.1136/bmjopen-2021-057510

Supplementary Figure 5. Period prevalence of primary care patients with hypertension and with antihypertensive drug prescriptions, stratified by antihypertensive drug class.

Abbreviations: ACE inhibitors, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; CCBs, calcium channel blockers

The vertical grey bars denote the year of publication of hypertension management guidelines or guideline updates by the British Hypertension Society (BHS)1-3 and the National Institute for Health and Care Excellence (NICE), in collaboration with BHS4-5.

References
1. Swales JR, LE; Coope, JR; Pocock, SJ; Robertson, JIS; Sever, PS; Shaper, AG. Treating mild hypertension. BMJ. 1989;298:694-698.
Supplementary Figure 6. Period prevalence of primary care patients with heart failure and with antihypertensive drug prescriptions, stratified by antihypertensive drug class

Abbreviations: ACE inhibitors, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; CCBs, calcium channel blockers

*a The vertical grey bars denote the year of publication of heart failure management guidelines or guideline updates by the European Society of Cardiology (ESC).

References
5. McMurray JJV, Adamopoulos S, Anker SD, et al. Esc guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the task force for the diagnosis and treatment of acute and chronic heart failure 2012 of the European Society of cardiology. Developed in collaboration with the heart failure association (HFA) of the ESC. Eur Heart J 2012;33:1787–847.
6. Ponikowski P, Voors AA, Anker SD. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;37(27), 2129-2200.
**Supplementary Figure 7.** Period prevalence of primary care patients with coronary heart disease and with antihypertensive drug prescriptions, stratified by antihypertensive drug class

Abbreviations: ACE inhibitors, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; CCBs, calcium channel blockers
**Supplementary Figure 8.** Period prevalence of primary care patients with diabetes and with antihypertensive drug prescriptions, stratified by antihypertensive drug class

Abbreviations: ACE inhibitors, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; CCBs, calcium channel blockers
**Supplementary Figure 9.** Period prevalence of primary care patients with chronic kidney disease and antihypertensive drug prescriptions, stratified by antihypertensive drug class.\(^a,b\)

Abbreviations: ACE inhibitors, angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor blockers; CCBs, calcium channel blockers

\(^a\) Year 1988 was suppressed due to small cell count (<5 patients) as per Clinical Practice Research Datalink policy.

\(^b\) The vertical grey bar marks the introduction of the Quality and Outcomes Framework for chronic kidney disease (CKD) in England in February 2006, which contained indicators of care to enhance the management of CKD. One incentivized indicator of care included the percentage of patients in the CKD register with a prescription for ACE inhibitors or ARBs.\(^1\) Further, UK guidelines for CKD management were published in March 2006 by the Royal College of Physicians, the Royal College of General Practitioners and the Renal Association.

**References**

Supplementary Figure 10. Study flow chart of patients with a first-ever antihypertensive drug prescription in monotherapy

Patients with a first prescription for an antihypertensive drug between January 1, 1988 and December 31, 2018
\( (n=2,701,885) \)

Excluded
\( 1,266,633 <1 \text{ year of medical history and date inconsistencies} \)

Patients with at least one year of medical history at first prescription
\( (n=1,435,252) \)

Excluded
\( 9,710 <18 \text{ years of age at first prescription} \)
\( 65,473 >1 \text{ prescription at cohort entry} \)

Adult patients with a first antihypertensive drug prescription in monotherapy
\( (n=1,360,069) \)
Supplementary Figure 11. Treatment trajectory of primary care patients with hypertension and a first-ever ARB or Other antihypertensive drug before January 1, 2007 a

Abbreviations: ACE inhibitor, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker

a Each concentric circle represents a treatment line. Percentages do not include patients who did not switch or added-on a new drug class.
Supplementary Figure 12. Median number of days (interquartile range) of each treatment line for primary care patients with hypertension with a first-ever antihypertensive drug prescription before January 1, 2007

Abbreviations: ACE inhibitor, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker

*a Each concentric circle represents a treatment line.
**Supplementary Figure 13.** Treatment trajectory of primary care patients with hypertension and a first-ever ARB or Other antihypertensive drug after January 1, 2007

Abbreviations: ACE inhibitor, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker

*Each concentric circle represents a treatment line. Percentages do not include patients who did not switch or added-on a new drug class.*
Supplementary Figure 14. Median number of days (interquartile range) of each treatment line for primary care patients with hypertension with a first-ever antihypertensive drug prescription after January 1, 2007

Abbreviations: ACE inhibitor, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker; CCB, calcium channel blocker

a Each concentric circle represents a treatment line.
b Cells <5 patients are suppressed as per Clinical Practice Research Datalink policy.
**Supplementary Figure 15.** Percentage of primary care patients with hypertension and antihypertensive drug prescriptions, stratified by number of antihypertensive drug classes prescribed after failure on first-line monotherapy.

*Some years were suppressed due to small cell count (<5 patients) as per Clinical Practice Research Datalink policy.*